Cluster Headaches Have New Trial Data. Ketamine Clinics Should Be Paying Attention
Clinicians call it the suicide headache. In separate studies, 47 percent and 55 percent of participants with cluster headache reported suicidal thoughts. Those figures come from different populations and should not be read as one settled prevalence. They do capture how heavy the psychiatric burden runs. Two small psilocybin studies published in 2024 have now added an intriguing signal, and it is worth understanding precisely what they did and did not show.
| Key Takeaway | Detail |
|---|---|
| The condition | Attacks last 15 to 180 minutes and can strike up to eight times a day |
| The psychiatric load | Separate studies reported suicidal thoughts in 47 percent and 55 percent of participants |
| The 2024 signal | Two small studies reported reduced attack frequency. Neither was a placebo controlled trial |
| The earlier trial | The 2022 placebo controlled study did not show a significant advantage over placebo |
| Where ketamine sits | Early and uncontrolled. An open label intranasal study missed its primary endpoint |
| The clinic role | Screen and refer to a headache neurologist. This is not a service to prepare to offer |
What the Condition Does
Cluster headache produces attacks around one eye. Each lasts 15 to 180 minutes. They can arrive up to eight times in a single day.
Episodic patients get attack periods lasting weeks or months. Chronic patients go a full year without a meaningful break. Roughly 10 to 20 percent of chronic cases resist available treatment.
That refractory group is small in percentage terms and desperate in practice. Most have tried everything on the standard list.
What the Standard List Looks Like
Abortive care leans on high flow oxygen and triptans such as sumatriptan. Ergotamine derivatives exist but see little use because of side effects.
Prevention runs through verapamil, lithium and topiramate. Galcanezumab is approved for episodic cluster headache specifically, not the chronic form.
What the 2024 Studies Actually Showed
Psilocybin and LSD have been studied for headache for more than 60 years. Both act on the same serotonin receptor. Two publications in 2024 renewed interest, and the details matter.
The US work reported the blinded extension phase of an earlier randomized trial. All 10 participants in that extension received psilocybin. Attack frequency fell by roughly 50 percent. Importantly, the original placebo controlled trial published in 2022 did not show a statistically significant advantage over placebo, and the placebo group there responded well.
The Danish study was an open label trial in 10 patients, with no placebo group. Attack frequency dropped about 31 percent. One participant reached 21 weeks of remission.
A Swiss case series of nine patients found six stopped having attacks after psilocybin or LSD. Two larger LSD trials are now underway. Read all of this as a signal worth testing, not as established efficacy.
The Doses Were Low, Not Microdoses
One detail gets misreported often. These protocols used repeated low doses of psilocybin rather than microdoses.
The doses were closely matched across both studies, at roughly 10 milligrams for a 70 kilogram adult. That is well above a microdose and below a full psychedelic session dose. Patients were not spending six hours in an altered state.
Where Ketamine Actually Sits
Ketamine has entered the cluster headache conversation, and the evidence remains early. Small case series have reported fewer attacks or temporary remission. Protocols and doses varied widely between them.
An open label intranasal study missed its primary endpoint. No controlled trial has established that ketamine works for cluster headache. Describe it to patients exactly that way and nothing more.
These Patients May Already Be Yours
Return to the psychiatric picture. Cluster headache patients carry substantially elevated rates of depression and suicidal thinking.
Many are already seeking treatment resistant depression care. Some are sitting in ketamine chairs now, with a headache history recorded in intake and treated as a separate problem elsewhere.
Noticing that costs one screening question. We covered the patient side in our earlier look at psychedelics and suicide headaches, and the broader pain evidence in our guide to ketamine for chronic pain.
The Access Picture
Oregon and Colorado currently provide regulated psilocybin access. New Mexico has authorized a medical program that is still being implemented, and cluster headache does not appear among its initial listed conditions.
Outside those state systems, access is generally limited to research and narrow special access pathways. Some patients treat themselves, which is part of why naturalistic use keeps appearing in headache research. That is not a pathway a clinic can recommend.
Serving a new patient population costs less when your supply and insurance lines are already optimized. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
What to Do With This
Refer first. A patient describing these attacks belongs with a headache neurologist for diagnosis and management. A monitoring room does not qualify a clinic to diagnose or treat cluster headache.
Screen for it. Add a headache question to intake. The overlap with your existing depression population is real, and catching it changes where you send someone.
Describe the evidence accurately. Psilocybin has produced an interesting signal in very small uncontrolled studies. Ketamine evidence for this indication is early and uncontrolled. Neither is an approved treatment for cluster headache.
Follow the LSD trials. Two are running with larger samples. If they produce controlled evidence, the conversation changes. Until then the right posture is screening, referral and attention, not preparing to offer a new service.
